MannKind Gains FDA Approval for Afrezza in Pediatric Diabetes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 MannKind Corporation announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 MannKind Corporation announced that the U.S. Food and Drug Administration...
